» Articles » PMID: 39086893

Excess Cardiovascular Mortality in Men with Non-alcoholic Fatty Liver Disease: A Cause for Concern!

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the commonest cause of chronic liver disease worldwide in recent years. With time, our understanding of NAFLD has evolved from an isolated liver condition to a systemic disease with significant manifestations beyond the liver. Amongst them, cardiovascular diseases (CVDs) are the most important and clinically relevant. Recent research supports a strong independent link between NALFD and CVD beyond the shared risk factors and pathophysiology. Female sex hormones are well known to not only protect against CVD in pre-menopausal females, but also contribute to improved adipose tissue function and preventing its systemic deposition. Recent research highlights the increased risk of major adverse cardiovascular-cerebral events (MACCE) amongst male with NAFLD compared to females. Further, racial variation was observed in MACCE outcomes in NAFLD, with excess mortality in the Native Americans and Asian Pacific Islanders compared to the other races.

Citing Articles

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Singh A, Sohal A, Batta A World J Gastroenterol. 2024; 30(48):5205-5211.

PMID: 39735270 PMC: 11612699. DOI: 10.3748/wjg.v30.i48.5205.


Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways.

Maiese K World J Cardiol. 2024; 16(11):632-643.

PMID: 39600987 PMC: 11586725. DOI: 10.4330/wjc.v16.i11.632.


Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease.

Singh A, Sohal A, Batta A World J Gastroenterol. 2024; 30(39):4324-4328.

PMID: 39492822 PMC: 11525852. DOI: 10.3748/wjg.v30.i39.4324.


Addressing the alarming link between nonalcoholic fatty liver disease and cardiovascular mortality in men.

Hao W, Cheng C, Cheng T World J Cardiol. 2024; 16(9):502-507.

PMID: 39351337 PMC: 11439102. DOI: 10.4330/wjc.v16.i9.502.

References
1.
Niederseer D, Wernly B, Aigner E, Stickel F, Datz C . NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021; 10(3). PMC: 7865665. DOI: 10.3390/jcm10030467. View

2.
Eberly L, Shultz K, Merino M, Brueckner M, Benally E, Tennison A . Cardiovascular Disease Burden and Outcomes Among American Indian and Alaska Native Medicare Beneficiaries. JAMA Netw Open. 2023; 6(9):e2334923. PMC: 10517375. DOI: 10.1001/jamanetworkopen.2023.34923. View

3.
Huang Y, Huang J, Chien H, Lin C, Chuang Y, Cheng H . Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk. Nutr Metab Cardiovasc Dis. 2023; 33(12):2479-2487. DOI: 10.1016/j.numecd.2023.08.005. View

4.
Petrescu M, Vlaicu S, Ciumarnean L, Milaciu M, Marginean C, Florea M . Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina (Kaunas). 2022; 58(5). PMC: 9147364. DOI: 10.3390/medicina58050641. View

5.
Yin X, Guo X, Liu Z, Wang J . Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2023; 24(3). PMC: 9917647. DOI: 10.3390/ijms24032844. View